Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001366353 | SCV001562654 | benign | Idiopathic generalized epilepsy; Hyperaldosteronism, familial, type IV | 2025-01-11 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002476672 | SCV002789267 | uncertain significance | Epilepsy, childhood absence, susceptibility to, 6; Hyperaldosteronism, familial, type IV | 2021-11-19 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003987853 | SCV004803899 | likely benign | not specified | 2024-01-19 | criteria provided, single submitter | clinical testing | Variant summary: CACNA1H c.1430G>A (p.Arg477His) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 3.4e-05 in 1552892 control chromosomes (i.e. 53 heterozygotes) in the gnomAD database, suggesting the variant is unlikely to be associated with an early onset, highly penetrant, autosomal dominant condition. To our knowledge, no occurrence of c.1430G>A in individuals affected with Idiopathic Generalized Epilepsy or other CACNA1H-associated disorders and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 1057384). Based on the evidence outlined above, the variant was classified as likely benign. |